Madrigal Pharmaceuticals stock target raised by analyst on Resmetirom optimism
MDGL
+1.89%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
On Tuesday, H.C. Wainwright updated its outlook on Madrigal Pharmaceuticals (NASDAQ:MDGL), increasing the price target to $405 from the previous $275 while maintaining a Buy rating on the stock. The firm’s analyst cited the impending FDA approval of Madrigal’s drug resmetirom as a key driver for the revision.
“Now just two days away, we believe the FDA approval of resmetirom is all but a certainty, establishing the drug as not only the first and only drug approved for MASH, but also, followed almost immediately, as the SoC treatment for this large and growing condition that is rapidly becoming the leading cause of liver transplantation in the U.S,” said the analyst.
Resmetirom, which has already received Breakthrough Therapy designation and Priority Review, is seen as a potential standard-of-care therapy for MASH. The drug is a once-daily, oral, liver-directed THR-β agonist that has shown positive effects across key aspects of the disease in clinical trials. The pivotal MAESTRO-NASH trial results, published in the New England Journal of Medicine, indicated significant improvements in liver health for patients on resmetirom.
The analyst also highlighted the safety profile of resmetirom, noting its similar incidence of serious adverse events (SAEs) to placebo and the transient nature of the most common side effects, such as diarrhea and nausea. These factors are expected to contribute to rapid physician trial and adoption following approval.
Madrigal is projected to enjoy a substantial period as the sole approved MASH therapy in the U.S., estimated to be over three years before competitors reach the market. This first-mover advantage is expected to facilitate the drug’s quick rise to blockbuster status and offer commercial benefits that are currently undervalued by the market.
In light of these factors, the revised financial model from H.C. Wainwright forecasts U.S. and EU peak revenues of $4.5 billion by 2033 for resmetirom, supporting the updated price target of $405 per share for Madrigal Pharmaceuticals. The firm’s positive outlook is anchored in the drug’s potential market dominance and the anticipated approval by the FDA within the week.
InvestingPro Insights
As Madrigal Pharmaceuticals (NASDAQ:MDGL) approaches a pivotal moment with the anticipated FDA approval of its drug resmetirom, the financial metrics and market sentiment surrounding the company provide additional context to the analyst’s optimistic forecast. According to real-time data from InvestingPro, Madrigal’s market capitalization stands at $5.18 billion, reflecting investor confidence in the company’s growth potential.
An InvestingPro Tip highlights that Madrigal holds more cash than debt on its balance sheet, suggesting a solid financial position to support its operations and drug development pipeline. Moreover, the company’s liquid assets exceed short-term obligations, providing further evidence of financial stability.
However, it’s worth noting that Madrigal is trading at a high Price / Book multiple of 12.77 as of the last twelve months ending Q4 2023, which might indicate a premium valuation compared to its tangible assets. This could be a reflection of the market’s expectations for the company’s future growth, particularly with the potential approval and commercialization of resmetirom.
The stock has also demonstrated strong returns with a 20.26% price increase over the last month and a 47.09% uptick over the last six months, signaling robust investor enthusiasm. These metrics, coupled with the positive analyst outlook, suggest that Madrigal might be well-positioned for future success, assuming the approval and successful market introduction of resmetirom.
For readers interested in a deeper analysis, there are additional InvestingPro Tips available, including insights on earnings revisions and profitability expectations. To access these valuable tips and make more informed investment decisions, visit InvestingPro and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 13 more InvestingPro Tips listed for Madrigal Pharmaceuticals, offering a comprehensive view of the company’s financial health and market performance.
